Date: 2014-04-07
Type of information: R&D agreement
Compound: innovative drugable targets
Company: MRC Technology (UK) Chinese Academy of Science (China)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism:
Disease: undisclosed
Details: * On November 29, 2012, MRC Technology, a technology transfer charity and company, has entered into a strategic drug discovery collaboration with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Science (CAS). The agreement will combine the SIBCB’s research expertise in generating potential new drug targets, with MRC Technology’s experience in further developing early stage research for pharmaceutical application and commercialisation. The focus of the collaboration is to fast track innovative drugable targets to create potent and selective novel therapeutics.
The collaboration was formalised at a signing ceremony held in Shanghai and attended by the senior team from both organisations including Dave Tapolczay and Michael Dalrymple (CEO and Director of Business Development, MRC Technology) and Professors Naihe Jing, Zhengjun Chen and Ge Jiang (Executive Director, Assistant Director and Head of Science and Technology respectively, SIBCB).
Supporting technology transfer and IP management efforts, MRC Technology set up its drug discovery laboratories in order to bridge the gap between innovative, early stage academic research and the development of intellectual property suitable for licensing to industry for further development and commercialisation. De-risking novel targets by providing proof of concept and pharma-quality data packages fulfils a clear need in the drug discovery process. The collaboration opens the MRC Technology laboratories up to a new source of targets from SIBCB researchers.
Financial terms:
Latest news: * On April 7, 2014, MRC Technology announced that it has extended its existing drug discovery collaboration with the Shanghai Institute of Biotechnology and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). In the new agreement MRC Technology will give SIBCB access to its unique compound library which will be used to screen novel targets derived from SIBCB research. The collaboration combines SIBCB’s research expertise in generating potential new drug targets with MRC Technology’s drug discovery experience in taking novel early stage targets through to lead/candidate stage small molecules. It aims to fast track innovative targets to create potent and selective novel therapeutics, support translational research in China and deliver validated projects to MRC Technology’s Centre for Therapeutics Discovery.
